We are live on ! Find out more
SPRY icon

ARS Pharmaceuticals
SPRY

61 hedge funds and large institutions have $114M invested in ARS Pharmaceuticals in 2022 Q3 according to their latest regulatory filings, with 13 funds opening new positions, 14 increasing their positions, 26 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

308% more call options, than puts

Call options by funds: $3.81M | Put options by funds: $933K

56% more capital invested

Capital invested by funds: $73.3M → $114M (+$41M)

11.63% more ownership

Funds ownership: 74.14% → 85.77% (+12%)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

5% less funds holding

Funds holding: 64 → 61 (-3)

19% less first-time investments, than exits

New positions opened: 13 | Existing positions closed: 16

46% less repeat investments, than reductions

Existing positions increased: 14 | Existing positions reduced: 26

Holders
61
Holders Change
-3
Holders Change %
-4.69%
% of All Funds
1.05%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
13
Increased
14
Reduced
26
Closed
16
Calls
$3.81M
Puts
$933K
Net Calls
+$2.88M
Net Calls Change
+$4.02M

Top Buyers

Rank Fund Capital Flow
1
RCMNY
Rubric Capital Management (New York)
New York
+$8.42M
2
KPF
K2 Principal Fund
Ontario, Canada
+$8.41M
3
SAM
Sectoral Asset Management
Quebec, Canada
+$5.15M
4
Fidelity Investments
Fidelity Investments
Massachusetts
+$5.15M
5
WP
Woodline Partners
California
+$4.01M

Top Sellers

Rank Fund Capital Flow
1
EC
EcoR1 Capital
California
-$2.44M
2
Renaissance Technologies
Renaissance Technologies
New York
-$1.16M
3
Bank of America
Bank of America
North Carolina
-$1.15M
4
Morgan Stanley
Morgan Stanley
New York
-$894K
5
SCM
Silverarc Capital Management
Massachusetts
-$887K
Name Holding Trade Value Shares
Change 		Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$25.2M +$5.15M +1,045,097 +28%
KPF
2
K2 Principal Fund
Ontario, Canada
$16.9M +$8.41M +1,705,827 +111%
RCMNY
3
Rubric Capital Management (New York)
New York
$14.2M +$8.42M +1,708,717 +173%
NI
4
Nextech Invest
Switzerland
$10.1M – – –
NCM
5
Nantahala Capital Management
Connecticut
$6.6M -$672K -136,275 -10%
Vanguard Group
6
Vanguard Group
Pennsylvania
$5.74M +$150K +30,507 +3%
SAM
7
Sectoral Asset Management
Quebec, Canada
$5.52M +$5.15M +1,045,234 New
WP
8
Woodline Partners
California
$4.29M +$4.01M +812,899 New
BlackRock
9
BlackRock
New York
$3.84M +$97.9K +19,859 +3%
Jacobs Levy Equity Management
10
Jacobs Levy Equity Management
New Jersey
$2.38M +$2.22M +450,834 New
TCM
11
Tang Capital Management
California
$2.16M +$2.02M +409,463 New
Millennium Management
12
Millennium Management
New York
$1.84M -$521K -105,771 -23%
Dimensional Fund Advisors
13
Dimensional Fund Advisors
Texas
$1.75M +$1.31M +266,613 +416%
OMC
14
Oasis Management Company
Cayman Islands
$1.68M – – –
Renaissance Technologies
15
Renaissance Technologies
New York
$1.66M -$1.16M -234,899 -43%
Two Sigma Advisers
16
Two Sigma Advisers
New York
$1.43M -$773K -156,900 -37%
Geode Capital Management
17
Geode Capital Management
Massachusetts
$1.18M +$3.61K +732 +0.3%
PM
18
Prosight Management
Texas
$1.04M -$714K -144,851 -42%
NYLIM
19
New York Life Investment Management
New York
$762K +$56.3K +11,418 +9%
Two Sigma Investments
20
Two Sigma Investments
New York
$617K -$378K -76,700 -40%
Goldman Sachs
21
Goldman Sachs
New York
$526K -$116K -23,634 -19%
Citadel Advisors
22
Citadel Advisors
Florida
$515K -$661K -134,196 -58%
BCM
23
Bridgeway Capital Management
Texas
$508K +$150K +30,344 +46%
Janney Montgomery Scott
24
Janney Montgomery Scott
Pennsylvania
$433K -$31.7K -6,425 -7%
E
25
Ergoteles
New York
$394K -$107K -21,756 -23%
1
2 3 4

SPRY Hedge Fund Activity: Q3 2022 in Review

61 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in ARS Pharmaceuticals (SPRY) for Q3 2022, worth a combined $114M — up 56% from $73.3M a quarter earlier.

Sellers outnumbered buyers: 16 funds closed out of SPRY and 13 opened new positions — a net loss of 3 holders — while 26 trimmed existing stakes and 14 added.

The largest buyer was Rubric Capital Management (New York), adding an estimated $8.42M. The largest seller was EcoR1 Capital, exiting entirely with an estimated $2.44M sold.

  • 61 institutional investors held ARS Pharmaceuticals (SPRY) as of Q3 2022, down from 64 in Q2 2022.
  • Funds reported $114M of ARS Pharmaceuticals stock for Q3 2022, up 56% quarter-over-quarter.
  • 13 funds opened new ARS Pharmaceuticals positions in Q3 2022 and 16 closed out, a net change of -3 holders.
  • The largest ARS Pharmaceuticals buyer in Q3 2022 was Rubric Capital Management (New York), an estimated $8.42M added.
  • The largest ARS Pharmaceuticals seller in Q3 2022 was EcoR1 Capital, an estimated $2.44M sold.

Based on aggregated 13F filings for Q3 2022.